Alpha1Health.com | Information about Managing your AAT Deficient Patient | Articles

Articles

Alpha1Health.com Survey

Take the Alpha1Health.com Survey

Take our survey to help us best meet the needs of the Alpha-1 community.

 

ARALAST

ARALAST

Choose a therapy that offers you the support you need.

 

For reprints, contact your Baxter/ARALAST representative at 1-866-ARALAST (272-5278).

Alpha1-antitrypsin deficiency: incidence and detection program. Campbell EJ. Respir Med. 2000;94(suppl C):S18-S21.

Alpha1-Antitrypsin deficiency: Memorandum from WHO meeting. World Health Organization. Bulletin of the World Health Organization. 1997;75:397-415.

American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818-900.

Biochemical efficacy and safety of a new pooled human plasma alpha1- antitrypsin, Respitin. Stoller JK, Rouhani F, Brantly M, et al. Chest. 2002;122:66-74.

Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Seersholm N, Wencker M, Banik N, et al. Eur Respir J 1997;10:2260-2263

Longitudinal follow-Up of patients with alpha1-protease inhibitor deficiency before and during therapy with IV alpha1-protease inhibitor. Wencker M, Fuhrmann B, Banik N, Konietzko N. Chest 2001;119:737-744.

Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wencker M, Banik N, Buhl R, et al. Eur Respir J. 1998;11:428-433.

Screening for alpha1-Pi deficiency in patients with lung diseases. Wencker, M. Respir Med 2000;94(suppl C):S16-S17.

Survival and FEV1 Decline in Individuals with Severe Deficiency of Alpha-1
Antitrypsin. Alpha-1 Antitrypsin Deficiency Registry Study Group. Am J
Respir Crit Care Med. 1998;158:49-59.

Worldwide Racial and Ethnic Distribution of Alpha1-Antitrypsin Deficiency. de Serres FJ. Chest. 2002;122:1818-1829.

ARALAST [Alpha1-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

Please review the Important Safety Information and the Full Prescribing Information

adobe reader To view PDF, you will need Adobe® Acrobat® Reader® software.